{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:24:58Z","timestamp":1787775898837,"version":"build-2784847793"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Irritable bowel syndrome (IBS) is a common gastrointestinal disorder. Recent studies suggest the importance of gut flora in the pathophysiology of it. Therefore, antibiotics have demonstrated a substantial benefit to reduce gut flora. Having few side effects, and applying one-dose per day, we studied the effect of azithromycin to treat IBS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>One hundred and twenty-six patients enrolled a randomized, double-blind, placebo-controlled study. The treatment group received azithromycin in addition to common treatment. Patients were followed for 12 weeks. Patients completed daily diaries documenting their symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>One hundred and thirteen patients completed the study. The onset of relief occurred significantly sooner, and duration of relief was significantly longer in azithromycin group. Movement, abdominal pain, bloating, and gas were significantly better in azithromycin group. Monthly results showed superior relief in bloating, gas, overall symptom, and overall bloating during 3 months. Significantly more patients in azithromycin group felt relief in bloating and gas and had greater consistency relief in almost all weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In our study, azithromycin significantly relieved most symptoms, such as abdominal pain, bloating, and gas. Overall symptom and overall bloating were relieved significantly in more patients in the intervention group in all weeks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/2277-9175.192737","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T06:35:55Z","timestamp":1476945355000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The comparison of treatments with and without azithromycin in irritable bowel syndrome with diarrhea-predominant in gastrointestinal Clinic of Al-Zahra Hospital, Isfahan, Iran"],"prefix":"10.4103","volume":"5","author":[{"given":"Mohamadreza","family":"Yazdani","sequence":"first","affiliation":[{"name":"Department of Infectious Disease, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Aramesh","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahmatollah","family":"Rafiei","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, Islamic University, Najafabad Branch, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Daghaghzadeh","sequence":"additional","affiliation":[{"name":"Integrative Functional Gastroenterology Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyman","family":"Adibi","sequence":"additional","affiliation":[{"name":"Integrative Functional Gastroenterology Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,11,28]]},"reference":[{"key":"R1-20251008","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archinte.161.14.1733","article-title":"A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome","volume":"161","author":"Camilleri","year":"2001","journal-title":"Arch Intern Med"},{"key":"R2-20251008","first-page":"1867","article-title":"Management of irritable bowel syndrome \u2013 Cover article","author":"Viera","year":"2002","journal-title":"Pract Ther"},{"key":"R3-20251008","first-page":"253","article-title":"Epidemiological features of irritable bowel syndrome and its subtypes among Iranian adults","volume":"28","author":"Keshteli","year":"2015","journal-title":"Ann Gastroenterol"},{"key":"R4-20251008","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/2050640613501817","article-title":"Symptom pattern following a meal challenge test in patients with irritable bowel syndrome and healthy controls","volume":"1","author":"Posserud","year":"2013","journal-title":"United European Gastroenterol J"},{"key":"R5-20251008","first-page":"36","article-title":"Small bowel bacterial overgrowth in patients with irritable bowel syndrome: The first study in Iran","volume":"7","author":"Abbasi","year":"2015","journal-title":"Middle East J Dig Dis"},{"key":"R6-20251008","first-page":"455","article-title":"Antibiotics for the treatment of irritable bowel syndrome","volume":"7","author":"Basseri","year":"2011","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"R7-20251008","first-page":"273","article-title":"Management of irritable bowel syndrome","volume":"55","author":"Ford","year":"2009","journal-title":"Minerva Gastroenterol Dietol"},{"key":"R8-20251008","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"R9-20251008","first-page":"S1","article-title":"Irritable bowel syndrome in Iran: SEPAHAN systematic review no 1","volume":"3","author":"Jahangiri","year":"2012","journal-title":"Int J Prev Med"},{"key":"R10-20251008","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gutjnl-2013-305989","article-title":"A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea","volume":"63","author":"Garsed","year":"2014","journal-title":"Gut"},{"key":"R11-20251008","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/CEG.S29023","article-title":"Targeted therapies for diarrhea-predominant irritable bowel syndrome","volume":"5","author":"Olden","year":"2012","journal-title":"Clin Exp Gastroenterol"},{"key":"R12-20251008","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4172\/2165-8048.1000150","article-title":"Functional diseases of the digestive system: Irritable bowel syndrome","volume":"4","author":"Barbuti","year":"2014","journal-title":"Intern Med"},{"key":"R13-20251008","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cgh.2008.07.008","article-title":"Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome","volume":"7","author":"Ringel","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R14-20251008","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMcp0801447","article-title":"Clinical practice. Irritable bowel syndrome","volume":"358","author":"Mayer","year":"2008","journal-title":"N Engl J Med"},{"key":"R15-20251008","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1517\/14728214.2015.1013935","article-title":"Emerging drug for diarrhea predominant irritable bowel syndrome","volume":"20","author":"Deiana","year":"2015","journal-title":"Expert Opin Emerg Drugs"},{"key":"R16-20251008","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11894-006-0051-3","article-title":"Bacteria and irritable bowel syndrome: The evidence for small intestinal bacterial overgrowth","volume":"8","author":"Lee","year":"2006","journal-title":"Curr Gastroenterol Rep"},{"key":"R17-20251008","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1136\/gut.2007.133629","article-title":"The small intestinal bacterial overgrowth. Irritable bowel syndrome hypothesis: Implications for treatment","volume":"57","author":"Vanner","year":"2008","journal-title":"Gut"},{"key":"R18-20251008","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/gut.2006.108712","article-title":"Small intestinal bacterial overgrowth in patients with irritable bowel syndrome","volume":"56","author":"Posserud","year":"2007","journal-title":"Gut"},{"key":"R19-20251008","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/2040622312472008","article-title":"Rifaximin in irritable bowel syndrome: Rationale, evidence and clinical use","volume":"4","author":"Saadi","year":"2013","journal-title":"Ther Adv Chronic Dis"},{"key":"R20-20251008","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.3748\/wjg.v20.i10.2482","article-title":"Irritable bowel syndrome and small intestinal bacterial overgrowth: Meaningful association or unnecessary hype","volume":"20","author":"Ghoshal","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R21-20251008","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.3748\/wjg.v20.i10.2499","article-title":"Irritable bowel syndrome: The evolution of multi-dimensional looking and multidisciplinary treatments","volume":"20","author":"Chang","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R22-20251008","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/ajg.2011.355","article-title":"The efficacy and safety of rifaximin for the irritable bowel syndrome: A systematic review and meta-analysis","volume":"107","author":"Menees","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"R23-20251008","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1517\/14656566.2013.794223","article-title":"Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome","volume":"14","author":"Camilleri","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"R24-20251008","doi-asserted-by":"crossref","first-page":"A","DOI":"10.1016\/S0016-5085(08)62544-5","article-title":"T1390 rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: Short term treatment leading to long term sustained response","volume":"134","author":"Lembo","year":"2008","journal-title":"Gastroenterology"},{"key":"R25-20251008","doi-asserted-by":"crossref","first-page":"557","DOI":"10.7326\/0003-4819-145-8-200610170-00004","article-title":"The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: A randomized trial","volume":"145","author":"Pimentel","year":"2006","journal-title":"Ann Intern Med"},{"key":"R26-20251008","first-page":"412","article-title":"Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study","volume":"98","author":"Pimentel","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R27-20251008","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/MCG.0b013e3181a099a5","article-title":"Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution","volume":"43","author":"Parodi","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"R28-20251008","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4137\/CGast.S7382","article-title":"Rifaximin therapy of irritable bowel syndrome","volume":"5","author":"Koo","year":"2012","journal-title":"Clin Med Insights Gastroenterol"}],"container-title":["Advanced Biomedical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01679891-201605000-00188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:45:45Z","timestamp":1787773545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01679891-201605000-00188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4103\/2277-9175.192737","relation":{},"ISSN":["2277-9175"],"issn-type":[{"value":"2277-9175","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"2015-12-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}